Article

Affinity-matured CD72-targeting Nanobody CAR T-cells Enhance Elimination of Antigen-Low B-cell Malignancies

2025-05-15

Abstract excerpt

<h4>ABSTRACT</h4> <h4>Background</h4> Chimeric antigen receptor (CAR) T-cell therapies are highly efficacious for several different hematologic cancers. However, for most CAR T targets it is observed that low surface antigen density on tumors can significantly reduce therapeutic efficacy. Here, we explore this dynamic in the context of CD72, a surface antigen we recently found as a promising target for refractor...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 84d77185-e71e-5694-91ac-665b2067d26d
DOI: 10.1101/2025.05.09.653155

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Affinity-matured CD72-targeting Nanobody CAR T-cells Enhance Elimination of Antigen-Low B-cell MalignanciesDOI 10.1101/2025.05.09.653155Read

Framework humanization optimizes potency of anti-CD72 nanobody CAR-T cells for B-cell malignanciesSemantic proximity Read

Surface Proteomics Reveals CD72 as a Target for In Vitro –Evolved Nanobody-Based CAR-T Cells in KMT2A/MLL1 -Rearranged B-ALLSemantic proximity Read

Combinatorial T cell engineering eliminates on-target off-tumor toxicity of CD229 CAR T cells while maintaining anti-tumor activitySemantic proximity Read

Universal Dual-Target CAR-γδT Cells Targeting B7-H3 and IL13Rα2 for Glioblastoma TherapySemantic proximity Read

The Application of Nanobody in CAR-T TherapySemantic proximity Read

Knocking out CD70 rescues CD70-specific nanoCAR T cells from antigen induced exhaustionSemantic proximity Read

Design of a novel NanoCAR construct that compares well with a conventional ScFv-based CAR targeting BCMA on multiple myelomaSemantic proximity Read

Pooled screening for CAR function identifies novel IL13Rα2-targeted CARs for treatment of glioblastomaSemantic proximity Read

Harnessing the CD2 axis to broaden and enhance the efficacy of CAR T cell therapiesSemantic proximity Read

IKAROS facilitates antigen escape in the face of CD19- and CD22-targeted therapies for B-cell acute lymphoblastic leukemiaSemantic proximity Read

Anti-CD22–chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemiaSemantic proximity Read

Precise Control of Switchable Chimeric Antigen Receptor T Cells Allows Enhanced Safety and Less T Cell ExhaustionSemantic proximity Read